Acuta Capital Partners’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-109,000
| Closed | -$4.57M | – | 34 |
|
|
2024
Q1 | $4.57M | Buy |
109,000
+39,600
| +57% | +$1.66M | 2.97% | 14 |
|
|
2023
Q4 | $2.75M | Sell |
69,400
-52,941
| -43% | -$2.1M | 1.55% | 23 |
|
|
2023
Q3 | $3.37M | Sell |
122,341
-2
| -0% | -$55 | 2.26% | 17 |
|
|
2023
Q2 | $4.15M | Buy |
122,343
+843
| +0.7% | +$28.6K | 2.81% | 15 |
|
|
2023
Q1 | $4.37M | Buy |
121,500
+6,500
| +6% | +$234K | 3.22% | 14 |
|
|
2022
Q4 | $5.13M | Sell |
115,000
-152,195
| -57% | -$6.78M | 3.15% | 15 |
|
|
2022
Q3 | $7.51M | Hold |
267,195
| – | – | 3.23% | 9 |
|
|
2022
Q2 | $7.2M | Sell |
267,195
-55,703
| -17% | -$1.5M | 4.01% | 8 |
|
|
2022
Q1 | $11M | Sell |
322,898
-17,200
| -5% | -$586K | 5.14% | 4 |
|
|
2021
Q4 | $13.1M | Buy |
340,098
+2,598
| +0.8% | +$100K | 5.52% | 4 |
|
|
2021
Q3 | $18.2M | Sell |
337,500
-649,906
| -66% | -$35.1M | 6.43% | 4 |
|
|
2021
Q2 | $33M | Sell |
987,406
-30,118
| -3% | -$1.01M | 13.19% | 2 |
|
|
2021
Q1 | $21M | Sell |
1,017,524
-609,976
| -37% | -$12.6M | 7.56% | 2 |
|
|
2020
Q4 | $28.5M | Buy |
1,627,500
+82,500
| +5% | +$1.45M | 7.76% | 1 |
|
|
2020
Q3 | $22.9M | Buy |
1,545,000
+545,000
| +55% | +$8.08M | 6.22% | 3 |
|
|
2020
Q2 | $13M | Buy |
+1,000,000
| New | +$13M | 3.76% | 8 |
|